NasdaqGM:FHTXBiotechs
Foghorn Therapeutics (FHTX) FY 2025 Losses Reinforce Bearish Unprofitability Narrative
Foghorn Therapeutics (FHTX) has posted its FY 2025 results with Q4 revenue of US$9.2 million and a basic EPS loss of US$0.34, alongside a trailing twelve month revenue base of US$30.9 million and EPS of US$1.18 in losses. Over recent quarters the company has seen revenue move from US$5.9 million in Q1 2025 to US$9.2 million in Q4, while quarterly EPS losses have ranged between US$0.25 and US$0.34. This sets the scene for investors to weigh the revenue run rate against ongoing net losses...